Rubella Virus

For adults who do not have documented evidence of immunity (such as a positive blood test for rubella IgG antibodies or written records of previous vaccination), the standard dosage is:

• Primary Immunization: A single 0.5 mL dose administered subcutaneously.
• Healthcare Personnel: Often required to have two doses of an MMR combination vaccine, spaced at least 28 days apart, if they lack immunity.
• Women of Childbearing Age: It is critical to ensure immunity before pregnancy. If a woman is found to be non-immune, she should receive one dose and be advised to avoid pregnancy for at least 28 days following vaccination.

The Rubella Virus vaccine is a routine part of the childhood immunization schedule in the United States and most other countries. The recommended schedule is:

• First Dose: 0.5 mL administered at 12 through 15 months of age.
• Second Dose: 0.5 mL administered at 4 through 6 years of age (before entering school).
• Infants in Outbreak Settings: In specific high-risk or travel scenarios, infants as young as 6 months may receive a dose, though this does not count toward the two-dose primary series because maternal antibodies may interfere with the immune response.

Renal Impairment

No dosage adjustments are required for patients with renal impairment, as the vaccine is not cleared by the kidneys. However, the overall health status of the patient should be evaluated by a healthcare provider.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic impairment. The liver does not play a role in the replication or clearance of the attenuated rubella virus.

Elderly Patients

Clinical studies of the rubella vaccine generally did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Most elderly individuals are presumed to be immune due to natural exposure in the pre-vaccine era, but vaccination is safe if immunity cannot be confirmed.

Rubella Virus is administered by a healthcare professional in a clinical setting. It is not for self-administration.

• Route: Subcutaneous (SC) injection only. It is typically injected into the fatty tissue of the upper arm (deltoid area) in adults and older children, or the fatty tissue of the anterolateral thigh in infants.
• Preparation: The lyophilized powder must be reconstituted with the provided diluent. The vial should be agitated gently to ensure complete dissolution. The resulting solution should be clear and yellow. If the solution is cloudy or contains particulate matter, it should not be used.
• Timing: The vaccine should be administered immediately after reconstitution. If not used within 8 hours, it must be discarded.
• Storage: Before reconstitution, the vaccine must be stored in a refrigerator (36°F to 46°F or 2°C to 8°C) and protected from light, which can inactivate the live virus.

If a child misses a scheduled dose of the MMR or rubella vaccine, it should be administered at the next available opportunity. There is no need to 'restart' the series; the second dose can be given as long as at least 28 days have passed since the first dose. Adults who realize they are non-immune should schedule a vaccination as soon as possible with their healthcare provider.

Because the vaccine is administered by healthcare professionals in single-dose vials or pre-filled syringes, an 'overdose' in the traditional sense is extremely rare. If multiple doses were accidentally administered simultaneously, the primary concern would be an increase in the intensity of local injection site reactions or a more robust systemic response (fever, rash). No specific emergency measures are typically required other than monitoring for adverse reactions and providing supportive care (e.g., acetaminophen for fever).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip scheduled immunizations without medical guidance. If you have questions about the schedule, consult the CDC's recommended immunization tables.

Most individuals experience mild reactions following the administration of the Rubella Virus vaccine. These are signs that the body is building an immune response. Common side effects include:

• Injection Site Reactions: Redness, swelling, soreness, or a small lump at the site of the injection. This typically appears within 24 hours and resolves within 2-3 days.
• Low-Grade Fever: A mild temperature (usually under 101°F) may develop 7 to 12 days after vaccination, coinciding with the peak of viral replication.
• Mild Rash: A faint, non-itchy rash may appear 1 to 3 weeks after the injection. This is often described as 'mini-rubella' and is not contagious.

• Lymphadenopathy: Swelling of the lymph nodes, particularly in the neck or behind the ears. This is a common response to live viral replication.
• Arthralgia (Joint Pain): This is specifically common in post-pubertal females (up to 25% of vaccinated women). It usually affects the small joints of the hands and feet and begins 1 to 3 weeks after vaccination, lasting for 1 to 3 weeks.
• Malaise and Fatigue: A general feeling of being unwell or tired as the immune system works.

• Thrombocytopenia: A temporary decrease in blood platelets (the cells that help blood clot). This is rare (approximately 1 in 30,000 to 40,000 doses) and is usually self-limiting, but it requires medical monitoring.
• Parasthesia: Tingling or 'pins and needles' sensations.
• Orchitis: Swelling of the testicles (extremely rare, more often associated with the mumps component of MMR).

While extremely rare, serious allergic or neurological reactions can occur.

> Warning: Stop taking Rubella Virus (seek emergency care) and call your doctor immediately if you experience any of these:

• Anaphylaxis: Signs include hives, swelling of the face or throat, difficulty breathing, rapid heartbeat, and dizziness. This usually occurs within minutes of the injection.
• Seizures: Often associated with a high fever (febrile seizures) in young children.
• Encephalitis or Encephalopathy: Inflammation of the brain. This is estimated to occur in fewer than 1 in 1,000,000 doses—significantly lower than the risk of encephalitis from a natural rubella infection.
• Severe Vision Changes: Inflammation of the optic nerve (optic neuritis).

There is no credible scientific evidence linking the Rubella Virus vaccine to long-term chronic conditions such as autism, Type 1 diabetes, or inflammatory bowel disease. Extensive global studies involving millions of children have consistently shown the vaccine to be safe. In rare cases, the joint pain (arthritis) associated with the vaccine in adult women can become recurrent or chronic, though this is much less common than the chronic arthritis that can follow a natural rubella infection.

No FDA black box warnings exist for Rubella Virus. However, the vaccine carries a significant contraindication regarding pregnancy, which is often highlighted prominently in the prescribing information (see Warnings section).

Report any unusual symptoms or suspected side effects to your healthcare provider. In the United States, you or your provider can also report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Rubella Virus (Live Attenuated) is a biological product that must be administered with caution in certain populations. The most critical safety point is that this is a live virus. While it is weakened, it can still replicate, which poses a risk to individuals with severely compromised immune systems.

No FDA black box warnings for Rubella Virus. However, the manufacturer's labeling includes a 'Warning' section regarding the theoretical risk to the fetus if administered during pregnancy.

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of anaphylactic reactions to neomycin or gelatin should not receive this vaccine, as these substances are used in the manufacturing and stabilization process. A history of contact dermatitis from neomycin is not a contraindication, as that is a delayed-type hypersensitivity rather than a life-threatening immediate reaction.
• Immunosuppression: Individuals with primary or acquired immunodeficiency states (e.g., leukemia, lymphoma, AIDS, or those receiving high-dose systemic corticosteroids or chemotherapy) should generally not receive live viral vaccines. The virus may replicate unchecked in these individuals, leading to severe complications.
• Febrile Illness: Vaccination should be postponed in individuals with an acute severe febrile illness (high fever). A minor illness, such as a common cold or low-grade fever, is not usually a reason to delay vaccination.
• Family History of Seizures: While not a contraindication, healthcare providers should be aware if a child has a personal or family history of seizures, as the fever following vaccination (usually 7-12 days later) could trigger a febrile seizure.

There are no routine laboratory tests (like blood counts or liver enzymes) required specifically for the rubella vaccine. However, in certain clinical scenarios, your doctor may perform:

• Rubella Titer (IgG): To confirm that the vaccine successfully induced immunity.
• Platelet Count: If symptoms of easy bruising or bleeding occur (to check for rare thrombocytopenia).

There is no evidence that the Rubella Virus vaccine affects the ability to drive or operate heavy machinery. Most patients can return to their normal activities immediately after vaccination, provided they do not feel faint or dizzy.

There are no known direct interactions between alcohol and the Rubella Virus vaccine. However, alcohol can sometimes mask the symptoms of a vaccine reaction or contribute to dehydration, so moderation is advised following any immunization.

As this is typically a one- or two-dose vaccine rather than a daily medication, 'discontinuation' is not applicable in the traditional sense. However, if a patient has a severe allergic reaction to the first dose, they must not receive a second dose of any vaccine containing rubella virus.

> Important: Discuss all your medical conditions, especially any immune system issues or allergies, with your healthcare provider before starting Rubella Virus.

• Immunosuppressive Therapies: Drugs such as high-dose corticosteroids (e.g., prednisone >20mg/day for more than 2 weeks), chemotherapy, and certain biologic modifiers (TNF-blockers) can suppress the immune system to the point where the live attenuated virus could cause systemic infection. Vaccination should be delayed until these therapies are completed.
• Other Live Vaccines (Inappropriate Timing): If Rubella Virus is not given on the same day as other live viral vaccines (like Varicella or Yellow Fever), the doses should be separated by at least 4 weeks. Giving them too close together can result in the first vaccine's immune response interfering with the second vaccine's replication, reducing efficacy.

• Immune Globulin (IG) and Blood Products: If you have recently received a blood transfusion, plasma, or immune globulin, the rubella vaccine should be delayed for 3 to 11 months, depending on the product and dose. Exogenous antibodies in these blood products can neutralize the vaccine virus before it has a chance to stimulate your own immune system. Conversely, if the vaccine is given first, IG should not be given for at least 2 weeks.

• Tuberculin Skin Test (PPD): The rubella vaccine can temporarily suppress the body's response to a TB skin test, leading to a false-negative result. The PPD test should be performed either on the same day as vaccination or delayed for 4 to 6 weeks afterward.

There are no known interactions between the Rubella Virus vaccine and specific foods, including grapefruit, dairy, or high-fat meals. Nutrition does not affect the subcutaneous absorption or the subsequent immune response.

There are no documented interactions between the Rubella Virus vaccine and common herbal supplements like St. John's Wort or Ginkgo Biloba. However, supplements that strongly modulate the immune system should be discussed with a doctor.

• Rubella Serology: Shortly after vaccination, a person may test positive for Rubella IgM. This does not indicate a new 'wild' infection but rather the expected response to the vaccine.
• Interferon-Gamma Release Assays (IGRAs): Similar to the PPD skin test, live vaccines may interfere with the results of blood tests for tuberculosis.

For each major interaction, the mechanism is usually related to immune interference. Either the patient's immune system is too weak to control the vaccine virus, or external antibodies/immune responses prevent the vaccine from working. Management involves careful timing and scheduling of doses.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as well as any recent blood transfusions or other vaccines.

Conditions where Rubella Virus must NEVER be used include:

• Pregnancy: Because the rubella virus can cross the placenta and potentially infect the fetus, the vaccine is strictly contraindicated during pregnancy. While no cases of Congenital Rubella Syndrome have been documented from the vaccine virus itself, the risk is considered theoretical and must be avoided.
• Severe Immunodeficiency: This includes patients with AIDS, severe combined immunodeficiency (SCID), or those undergoing intensive immunosuppressive treatment for cancer or organ transplants. The risk of disseminated viral infection is too high.
• Severe Allergic Reaction (Anaphylaxis): To a previous dose of rubella-containing vaccine or to any of its components, including neomycin and gelatin.

Conditions requiring careful risk-benefit analysis by a physician:

• Acute Moderate or Severe Illness: Vaccination is usually deferred until the patient recovers to ensure that vaccine side effects do not confuse the clinical picture of the illness.
• Recent Receipt of Blood Products: Requires a waiting period to ensure the vaccine will be effective.
• History of Thrombocytopenia: Patients who developed low platelets after a previous dose of MMR may be at higher risk for recurrence, though the benefits of immunity usually outweigh the risks.

Patients who are allergic to neomycin (an antibiotic used in many topical creams) may have a cross-sensitivity to the trace amounts of neomycin found in the vaccine. Similarly, those with severe allergies to porcine gelatin (used as a stabilizer) must be identified, as the vaccine contains this ingredient.

> Important: Your healthcare provider will evaluate your complete medical history and any potential allergies before prescribing Rubella Virus.

FDA Pregnancy Category: C (Contraindicated).

Women should be advised not to become pregnant for at least 28 days (one month) after receiving the Rubella Virus vaccine. If a woman is accidentally vaccinated during pregnancy or becomes pregnant within 28 days of vaccination, she should be counseled on the theoretical risk to the fetus. However, data from thousands of accidental vaccinations during pregnancy have shown no evidence of Congenital Rubella Syndrome, so vaccination is not generally considered a reason to terminate a pregnancy.

Rubella Virus (live attenuated) may be secreted in human milk. While the virus can be passed to the nursing infant, it rarely causes symptoms. Breastfeeding is not a contraindication to rubella vaccination; in fact, it is often recommended for non-immune mothers in the immediate postpartum period to ensure they are protected before their next pregnancy.

The vaccine is approved and highly recommended for children starting at 12 months of age. It is not generally recommended for infants under 12 months because the presence of maternal antibodies (passed through the placenta) can neutralize the vaccine and prevent the infant from developing their own long-term immunity.

Most adults born before 1957 are considered naturally immune to rubella. However, for those who are not, the vaccine is safe and effective. There are no specific age-related dosage adjustments, but providers should screen for underlying immunodeficiencies that are more common in older age.

No dose adjustment is necessary. The vaccine does not pose an increased risk to patients with kidney disease, provided their immune system is otherwise functioning normally.

No dose adjustment is necessary. Liver function does not affect the safety or efficacy of the Rubella Virus vaccine.

> Important: Special populations, particularly pregnant women and those with immune disorders, require individualized medical assessment before receiving any live vaccine.

Rubella Virus (Live Attenuated) acts as an active immunizing agent. The Wistar RA 27/3 strain is a live virus that has been 'attenuated' or weakened by passing it through human diploid cell cultures (WI-38) multiple times at low temperatures. This process causes the virus to lose its virulence (ability to cause disease) while retaining its immunogenicity (ability to trigger an immune response).

Upon administration, the virus infects host cells and replicates. Viral proteins are then expressed on the surface of infected cells and recognized by the host's immune system. This triggers the production of neutralizing IgG antibodies and activates T-cell mediated immunity. The presence of these 'memory' cells ensures that the body can quickly mount a defense upon future exposure to the wild-type virus.

• Onset of Effect: Antibodies typically become detectable 2 to 3 weeks after vaccination.
• Duration of Effect: In most individuals, a single dose provides lifelong immunity. However, a two-dose series is recommended to ensure that the small percentage of 'primary vaccine failures' (those who didn't respond to the first dose) are protected.
• Dose-Response: The standard 0.5 mL dose contains a minimum of 1,000 TCID50 (Tissue Culture Infectious Doses) of the virus, which is sufficient to induce seroconversion in over 95% of susceptible individuals.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Subcutaneous injection) |

| Protein Binding | N/A (Viral particles) |

| Half-life | N/A (Replicates for ~21 days) |

| Tmax | 7-12 days (Peak viral replication) |

| Metabolism | Intracellular viral processing |

| Excretion | Minimal nasopharyngeal shedding |

The active ingredient is a live, attenuated virus. It is not a single chemical molecule and thus does not have a standard molecular weight or formula. The virus consists of a single-stranded RNA genome enclosed in an icosahedral capsid and a lipid envelope containing E1 and E2 glycoproteins. It is soluble in the provided sterile diluent but is highly sensitive to heat and ultraviolet light.

Rubella Virus belongs to the class of Live Attenuated Viral Vaccines. It is often categorized within the broader therapeutic area of Immunologicals and Vaccines (ATC code: J07BJ01).